Lol...why am I even wasting my time. The product costs $23,500/year. $2b in sales divided by $23,500/year/patient equals only 85,000 patients. That is a ridiculous lowball. The Fool article is essentially assuming that the Oceanside and Denmark plants will never produce a drop of Tysabri. Preposterous.
Look more carefully at the table before you rant about it. The 375k patients figure you're referring to is the Fool's estimate for total patients treated on any drug worldwide, not total patients treated on tysabri. Look 2 rows under.
you are correct but it still 35% market penetration in the U.S. which is significant. If I used $3B in FY2010 sales its still a dog with 475M shares outstanding in FY2010. you don't get it do you! their is no bang for the share price in the next 30 months,,,, sell @$30, take the $$$$$ and run. I have not seen one analyst with a $3B projection by fy2010 and I think they no more than you or me.